Paeoniflorin might therefore have therapeutic potential as a preventive agent for patients who need to receive long-term high-dose IFN-α treatment and who are susceptible to depression, and particularly in patients with inflammatory disorders. Here, IFNA1 is linked to depressive symptom measurement.